+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alzheimer's Disease Drugs Market - Global Forecast 2026-2032- Product Image
Alzheimer's Disease Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Alzheimer's Disease Drugs Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905145
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alzheimer's Disease Drugs Market is projected to reach USD 5.46 Billion in 2026. It is expected to continue growing at a CAGR of 8.66%, reaching USD 9.02 Billion by 2032.

The Alzheimer’s disease drugs market is moving from a largely symptomatic-care model toward a more evidence-driven Alzheimer’s therapeutics ecosystem. Established cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, and the NMDA receptor antagonist memantine remain central to clinical management, while disease-modifying therapies targeting amyloid pathology are reshaping diagnosis, patient selection, reimbursement, and infusion-center capacity.

At the same time, safety monitoring for amyloid-related imaging abnormalities, biomarker confirmation requirements, boxed-warning considerations, and payer scrutiny continue to define adoption across the Alzheimer’s disease drugs market.

Transformative Shifts in the Alzheimer’s Therapeutics Landscape

The most important shift in the Alzheimer’s disease drugs landscape is the transition from late-stage symptom management to earlier, biomarker-supported intervention. This change increases demand for amyloid PET, cerebrospinal fluid testing, validated blood-based biomarkers, MRI monitoring, neurologist capacity, and integrated memory-care pathways.

Commercial strategy is also changing. Drug developers are prioritizing precision enrollment, earlier disease stages, combination approaches, subcutaneous administration options, and differentiated mechanisms including tau, neuroinflammation, synaptic dysfunction, and metabolic pathways. Market access teams must now address not only drug price, but also total system readiness, diagnostic infrastructure, infusion logistics, caregiver burden, adverse-event monitoring, and long-term evidence generation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across Alzheimer’s disease drug discovery, clinical development, diagnosis, and post-market surveillance. AI-enabled imaging analysis can support earlier detection of brain atrophy and amyloid-related safety signals, while machine learning models are increasingly used to identify high-risk populations, stratify patients, and improve trial enrichment.

In drug development, AI helps screen targets, analyze multi-omics datasets, model disease progression, identify digital biomarkers, and reduce protocol inefficiencies. Its commercial value depends on clinical validation, regulatory transparency, representative datasets, data privacy safeguards, and workflow integration. For industry leaders, AI is becoming less of a standalone tool and more of an operating layer that improves evidence generation across the Alzheimer’s disease drugs market.

Key Regional Insights Across Major Markets

North America remains the most commercially advanced region for Alzheimer’s disease drugs, led by the United States’ rapid regulatory pathway, specialist networks, clinical trial activity, biomarker testing capacity, and payer decisions. Canada shows strong clinical expertise and public-health awareness but more cautious reimbursement timing. Europe is shaped by centralized scientific review, national health technology assessment, pharmacovigilance requirements, and country-by-country access negotiations, making evidence quality, safety data, and cost-effectiveness critical.

Asia-Pacific is a major growth arena because aging populations in Japan, China, South Korea, India, and Australia are increasing dementia-care needs. Japan has been an early adopter of innovative Alzheimer’s therapies, while China and India offer large patient pools but uneven access to specialist diagnosis, amyloid confirmation, and advanced imaging. Latin America, led by Brazil and Mexico, is expanding specialist care and dementia awareness but faces affordability barriers and fragmented reimbursement. The Middle East, especially GCC health systems, is investing in advanced diagnostics, tertiary-care neurology, and health-system modernization, while Africa remains constrained by low diagnosis rates, limited specialist capacity, low availability of biomarker testing, and access gaps.

Key Group Insights for Strategic Market Planning

Within ASEAN, rising life expectancy, urban hospital expansion, and growing dementia awareness support long-term demand for Alzheimer’s disease drugs, although diagnosis, biomarker access, and reimbursement remain uneven across member states. The GCC is positioned for faster adoption of advanced diagnostics and specialty biologics because of concentrated healthcare investment, national health transformation programs, tertiary-care systems, and growing demand for neurology services.

The European Union emphasizes regulatory rigor, pharmacovigilance, health technology assessment, and equitable access, making real-world evidence essential for sustained adoption. BRICS markets combine large aging populations with variable affordability, diagnostic infrastructure, and reimbursement maturity, creating opportunities for differentiated access models and local partnerships. G7 countries lead in clinical research, regulatory science, specialist care, and early commercialization, while NATO members overlap significantly with high-income markets where supply resilience, data security, and cross-border research collaboration matter for Alzheimer’s therapeutics.

Key Country Insights for Alzheimer’s Disease Drugs

The United States is the pivotal Alzheimer’s disease drugs market due to FDA approvals, Medicare coverage influence, clinical trial density, advanced imaging networks, and broad specialist infrastructure. Canada and the United Kingdom combine strong research networks with evidence-based reimbursement review and structured health technology assessment. Germany and France are major European access markets with established neurology care, while Italy and Spain represent high-need aging populations with budget-sensitive adoption pathways.

China, Japan, South Korea, India, and Australia define much of Asia-Pacific’s future demand. Japan is a high-priority market because of population aging, advanced specialty care, and established dementia policy focus; China and India offer scale but require diagnostic expansion and broader access to memory clinics. Australia and South Korea show strong specialist capability and growing biomarker infrastructure. Brazil and Mexico anchor Latin American opportunity through large urban healthcare systems, while Russia has demand from an aging population but faces geopolitical, reimbursement, and access complexity. Across all countries, adoption depends on early diagnosis, biomarker availability, infusion capacity, MRI safety monitoring, clinician training, and payer confidence.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated Alzheimer’s care pathways that connect cognitive screening, biomarker confirmation, treatment eligibility, infusion delivery, MRI monitoring, adverse-event management, and caregiver support. Commercial success will depend on proving value across the full patient journey rather than focusing only on product efficacy.

Organizations should invest in real-world evidence, equitable diagnostic access, clinician education, payer-facing outcome models, and scalable safety-monitoring protocols. Strategic partnerships with imaging providers, laboratories, academic memory centers, health systems, and digital health platforms can reduce adoption friction. Pipeline leaders should also diversify beyond amyloid, as long-term market leadership will require differentiated efficacy, safer administration, scalable monitoring, and evidence in broader patient populations.

Research Methodology

This executive summary is based on structured secondary research using verified public sources, including regulatory approvals and prescribing information, clinical trial registries, peer-reviewed medical literature, public health data, treatment guidelines, pharmacovigilance communications, and health technology assessment materials. The analysis emphasizes substantiated market drivers rather than speculative claims.

The methodology applies triangulation across disease epidemiology, regulatory activity, treatment guidelines, competitive pipelines, regional access conditions, and healthcare infrastructure. Insights are assessed for consistency, recency, source quality, and commercial relevance. The approach supports industry analysis while maintaining factual accuracy for decision-makers evaluating the Alzheimer’s disease drugs market.

Conclusion

The Alzheimer’s disease drugs market has entered a new phase defined by disease-modifying therapies, biomarker-driven diagnosis, and growing demand for healthcare-system readiness. Anti-amyloid antibodies have validated a more intervention-oriented model, but safety monitoring, reimbursement complexity, diagnostic capacity, and treatment logistics will determine the pace of adoption.

Future progress will favor organizations that combine scientific differentiation with practical implementation. Leaders that invest in evidence generation, AI-enabled development, patient identification, access strategy, and regional healthcare partnerships will be best positioned as Alzheimer’s therapeutics evolve from symptomatic treatment toward precision, earlier-stage disease management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Alzheimer's Disease Drugs Market, by Drug Class
7.1. Introduction
7.2. Amyloid Beta-Targeting Agents
7.2.1. Amyloid Beta Antibodies
7.2.2. Beta-Secretase (BACE) Inhibitors
7.3. Cholinesterase Inhibitors
7.4. NMDA Receptor Antagonists
8. Alzheimer's Disease Drugs Market, by Drug Type
8.1. Introduction
8.2. Branded Drugs
8.3. Generic Drugs
9. Alzheimer's Disease Drugs Market, by Formulation
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous Infusion
9.2.2. Subcutaneous Injection
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
10. Alzheimer's Disease Drugs Market, by Line Of Therapy
10.1. Introduction
10.2. First-Line
10.3. Second-Line
10.4. Third-Line And Later
11. Alzheimer's Disease Drugs Market, by Development Stage
11.1. Introduction
11.2. Approved
11.3. Phase III
11.4. Phase II
11.5. Phase I
11.6. Preclinical
12. Alzheimer's Disease Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Alzheimer's Disease Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Alzheimer's Disease Drugs Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Alzheimer's Disease Drugs Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Alzheimer's Disease Drugs Market, by Country
16.1. China
16.2. United States
16.3. Japan
16.4. India
16.5. Germany
16.6. United Kingdom
16.7. Australia
16.8. France
16.9. South Korea
16.10. Italy
16.11. Canada
16.12. Russia
16.13. Brazil
16.14. Mexico
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc
18.2. AC Immune SA
18.3. Acadia Pharmaceuticals Inc.
18.4. Acumen Pharmaceuticals
18.5. Alector, Inc.
18.6. Alzheon Inc.
18.7. Amgen Inc
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Biogen Inc
18.11. BioVie Inc.
18.12. Bristol-Myers Squibb Company
18.13. Cassava Sciences Inc.
18.14. Cognition Therapeutics Inc.
18.15. Daiichi Sankyo Company Limited
18.16. Dr. Reddy’s Laboratories Ltd
18.17. Eisai Co Ltd
18.18. Eli Lilly and Company
18.19. F. Hoffmann-La Roche Ltd
18.20. GlaxoSmithKline PLC
18.21. H. Lundbeck A/S
18.22. Johnson & Johnson
18.23. Lupin Pharmaceuticals Inc
18.24. Merck & Co Inc
18.25. Novartis AG
18.26. Otsuka Pharmaceutical Co Ltd
18.27. Pfizer Inc
18.28. Roche Holding AG
18.29. Sanofi S.A
18.30. Sun Pharmaceutical Industries Ltd
18.31. Takeda Pharmaceutical Company Limited
18.32. TauRx Therapeutics Ltd
18.33. Teva Pharmaceutical Industries Ltd
List of Figures
FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AMYLOID BETA-TARGETING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AMYLOID BETA-TARGETING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AMYLOID BETA-TARGETING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AMYLOID BETA ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AMYLOID BETA ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AMYLOID BETA ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BETA-SECRETASE (BACE) INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL BETA-SECRETASE (BACE) INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL BETA-SECRETASE (BACE) INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL THIRD-LINE AND LATER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL THIRD-LINE AND LATER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL THIRD-LINE AND LATER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL APPROVED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL APPROVED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL APPROVED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 106. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 107. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 109. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 110. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 111. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 112. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 139. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 140. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 143. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 144. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 161. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 162. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 163. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 164. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 165. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 166. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 167. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 168. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 172. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 173. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 174. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 175. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 176. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 177. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 178. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 179. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 183. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 184. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 185. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 186. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 187. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 188. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 189. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 190. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 205. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 206. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 207. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 210. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 211. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 212. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 216. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 217. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 218. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 219. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 221. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 222. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 223. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 226. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 229. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 230. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 231. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 232. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 233. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 234. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 235. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 251. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 252. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 253. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 254. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 255. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 256. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 257. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 261. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 262. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 263. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 264. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 265. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 266. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 267. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 268. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 272. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 273. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 274. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 275. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 276. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 277. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 278. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 279. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 301. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 305. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 306. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 307. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 308. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 309. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 310. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 311. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 312. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 323. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 327. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 328. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 329. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 330. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 331. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 332. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 333. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 334. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 338. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2017-2032 (USD MILLION)
TABLE 339. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 340. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 341. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 342. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 343. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 344. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 345. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY EN

Companies Mentioned

  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Acumen Pharmaceuticals
  • Alector, Inc.
  • Alzheon Inc.
  • Amgen Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc
  • BioVie Inc.
  • Bristol‑Myers Squibb Company
  • Cassava Sciences Inc.
  • Cognition Therapeutics Inc.
  • Daiichi Sankyo Company Limited
  • Dr. Reddy’s Laboratories Ltd
  • Eisai Co Ltd
  • Eli Lilly and Company
  • F. Hoffmann‑La Roche Ltd
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi S.A
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • TauRx Therapeutics Ltd
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.02 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Alzheimer's Therapeutics Market - Global Forecast 2026-2032 - Product Image

Alzheimer's Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Alzheimer's Disease Diagnostics & Therapeutics Market - Global Forecast 2026-2032 - Product Image

Alzheimer's Disease Diagnostics & Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Alzheimer's Disease Drugs - Global Strategic Business Report - Product Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Alzheimer's Disease Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Alzheimer's Disease Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From
Alzheimer's Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Alzheimer's Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From

About the Alzheimer's Disease Drugs Market

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone. The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.